Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039377 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00039377: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00039377 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039377, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation may be an effective treatment for acute lymphoblastic leukemia.
Interventions
- DRUG imatinib mesylate
- DRUG leucovorin calcium
- DRUG methotrexate
- PROCEDURE peripheral blood stem cell transplantation
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2002-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039377
The ClinicalTrials.gov registry entry for NCT00039377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which imatinib mesylate is the first listed.
NCT00039377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039377 about?
NCT00039377 is a clinical study titled "Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they sto...
What is the current status of trial NCT00039377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2002-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00039377?
The interventions under investigation include: imatinib mesylate (DRUG), leucovorin calcium (DRUG), methotrexate (DRUG), peripheral blood stem cell transplantation (PROCEDURE), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00039377?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.